Compare Medpace Holdings Inc (MEDP) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Block Inc — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Block Inc trades at $77.28 (market cap $45.20B). The key difference: Block Inc is far larger — about 2.7× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Block Inc for 78 Days on average.
| MEDP | XYZ | |
|---|---|---|
Market Cap | $16.82B | $45.20B |
Volume | 223,093 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $630.19 | $84.85 |
52-Week Low | $393.42 | $49.04 |
Typical Hold Time | 14 Days | 78 Days |
Enterprise Value | $16.44B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Block (XYZ) trades at $77.24, up 1.54% today, with strong analyst support (77% buy ratings) and a $97.47 consensus price target suggesting 26% upside. Recent quarters show earnings momentum with Q1 and Q2 2026 beats, though Q3 2026 results are pending. Revenue growth has been steady, reaching $24.19B in 2025, but net margins remain thin at 1.43%. Technical indicators are bearish overall, with the stock testing resistance near $77.
The stock offers growth potential from expanding Square and Cash App ecosystems and new banking initiatives, but faces risks from high P/E valuation (134.34), competitive pressures, and insider selling. Positive earnings surprises and institutional accumulation provide support, though profitability consistency and debt levels warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
